Mpex Successor Rempex Snags up to $67.5M in Series B
Rempex Pharmaceuticals Inc., formed in June to acquire the human, financial and clinical assets unrelated to Aeroquin from Mpex Pharmaceuticals Inc., has attracted a commitment of up to $67.5 million to advance the development of treatments for resistant Gram-negative infections.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter